Rozzano

• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Not authorised
  2022-500536-11-00 5 Moderately to severely active ulcerative colitis
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 5 Moderately to severely active ulcerative colitis
• A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Pati … Not authorised
  2022-502043-35-00 5 Advanced Biliary Tract Cancers
• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 5 Ulcerative colitis
• Progression under Olaparib: a randomized phaSE II trIal with docetaxel or carboplatin-docetaxel DOublet in mCRPC patieNts Pending
  2023-503676-25-01 4 prostate cancer
• A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l … Pending
  2024-512195-35-00 5 Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-p
• A 52 week study in which neither Sponsor or participant know the treatment assigned to subjects to compare the experimental drug (CHF 5993) … Pending
  2024-514248-95-00 5 Uncontrolled Asthma
• A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung … Pending
  2024-514701-57-01 4 non Small Cell Lung Cancer
• A study testing the new drug Lisaftoclax for newly diagnosed acute myeloid leukemia(GLORA-3) Pending
  2024-516436-10-00 5 Acute myeloid leukemia
• A Phase II, Open-Label, Single-Arm, Multicentre Study of Carboplatin, Paclitaxel, and Tislelizumab in Biomarker-Selected Patients with Resec … Pending
  2024-517565-16-00 4 Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma
• Use of Sulodexide (VESSEL®) for the prevention of a new episode in elderly patients who have had a first episode of deep vein thrombosis and … Pending
  2024-517796-21-00 5 Prevention of recurrence after a first episode of Venous Thromboemboli
• A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY … Pending
  2024-517861-18-00 5 Idiopathic IgA nephropathy (IgAN)
• Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO trial) Pending
  2024-518388-37-00 4 Intermediate risk prostate cancer
• Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults with Non-cystic Fibrosis Bronchiectasis (NCFB) Pending
  2024-518821-13-00 4 Non-cystic Fibrosis Bronchiectasis
• Evaluation of the efficacy and safety of Magnetic Resonance Angiography (MRA) using gadopiclenol compared to gadoterate meglumine in the ass … Pending
  2024-518835-13-00 5 Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar),
• A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III … Pending
  2024-519031-42-00 5 pancreatic ductal adenocarcinoma
• Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with … Pending
  2024-519106-12-00 4 Patients with anaplastic lymphoma kinase positive (ALK+) locally advan
• Stereotactic body radiation therapy on Prostate with or without Androgen deprivation therapy, a phase III randomized controlled trial (SPA T … Pending
  2024-520093-34-00 5 Acinar cell prostatic carcinoma
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Pending
  2025-521038-27-00 5 Immune system diseases
• Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study Pending
  2025-521583-35-00 4 non-small cell lung cancer (NSCLC)
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 5 Moderately to Severely Active Crohn’s Disease
• Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o … Pending
  2025-521632-12-00 5 Patients on Factor Xa inhibitor treatment needing an urgent interventi
• PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Li … Pending
  2025-521666-10-01 4 Mantle Cell Lymphoma

Showing 1–24 of 692 trials